Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Scientific filings document the company’s public reporting for its common stock and Nasdaq-listed warrants, including CORZZ tranche 2 warrants exercisable for common stock at a $0.01 exercise price. The records identify Core Scientific as a digital infrastructure business with bitcoin self-mining, digital asset hosting and high-density colocation operations.
Recent 8-K filings cover operating and financial results, Regulation FD materials, material definitive agreements, securities registered under Section 12(b), senior secured notes due 2031, capital-structure disclosures, subsidiary financing arrangements and governance matters such as officer appointments and compensation arrangements.
Jane Street Group, LLC reports beneficial ownership of 23,967,780 shares of Core Scientific, Inc./tx common stock, representing 7.5% of the class. The filing identifies subsidiary holdings: Jane Street Capital, LLC (20,703,298 shares; 6.5%) and Jane Street Global Trading, LLC (3,264,482 shares; 1.0%). The statement shows shared voting and shared dispositive power over the 23,967,780 shares and is signed by Jeremy Kahn as authorized signatory.
Jane Street Group, LLC reports beneficial ownership of 23,967,780 shares of Core Scientific, Inc./tx common stock, representing 7.5% of the class. The filing identifies subsidiary holdings: Jane Street Capital, LLC (20,703,298 shares; 6.5%) and Jane Street Global Trading, LLC (3,264,482 shares; 1.0%). The statement shows shared voting and shared dispositive power over the 23,967,780 shares and is signed by Jeremy Kahn as authorized signatory.
Core Scientific, Inc. appointed Steve M. Smith to its Board of Directors and its Nominating and Corporate Governance Committee, effective immediately. The company describes itself as a leader in digital infrastructure for high-density colocation serving AI-related workloads.
Smith, age 70, is currently Chief Executive Officer of Zayo Group and previously served as CEO and President of Equinix from 2007 to 2018, where he helped grow annual revenue from about $400 million to more than $4 billion and integrated over 20 acquisitions. The Board has determined he is independent under Sarbanes-Oxley and Nasdaq rules, and he will receive cash and equity compensation consistent with other non-employee directors. There are no family relationships or related-party transactions disclosed. Core Scientific notes that its majority revenue comes from high-density colocation services as it repurposes remaining mining facilities to support this business.
Core Scientific, Inc. appointed Steve M. Smith to its Board of Directors and its Nominating and Corporate Governance Committee, effective immediately. The company describes itself as a leader in digital infrastructure for high-density colocation serving AI-related workloads.
Smith, age 70, is currently Chief Executive Officer of Zayo Group and previously served as CEO and President of Equinix from 2007 to 2018, where he helped grow annual revenue from about $400 million to more than $4 billion and integrated over 20 acquisitions. The Board has determined he is independent under Sarbanes-Oxley and Nasdaq rules, and he will receive cash and equity compensation consistent with other non-employee directors. There are no family relationships or related-party transactions disclosed. Core Scientific notes that its majority revenue comes from high-density colocation services as it repurposes remaining mining facilities to support this business.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class. The percentage is calculated using 317,885,292 shares outstanding as of May 1, 2026. The filing states the holding is reported jointly by Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen, with shared voting and shared dispositive power over the 16,213,103 shares. The reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated May 15, 2026.
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class. The percentage is calculated using 317,885,292 shares outstanding as of May 1, 2026. The filing states the holding is reported jointly by Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen, with shared voting and shared dispositive power over the 16,213,103 shares. The reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated May 15, 2026.
Core Scientific, Inc. - Joint Schedule 13G/A discloses passive ownership by Citadel-related entities and Kenneth Griffin. The filing reports that Citadel Securities LLC may be deemed to beneficially own 9,357,746 shares (3.0%) and that Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin may each be deemed to beneficially own 12,792,480 shares (4.1%) based on 315,596,127 Shares outstanding as of March 23, 2026. The statement describes shared voting and dispositive power and notes certain shares issuable upon conversion of warrants.
Core Scientific, Inc. - Joint Schedule 13G/A discloses passive ownership by Citadel-related entities and Kenneth Griffin. The filing reports that Citadel Securities LLC may be deemed to beneficially own 9,357,746 shares (3.0%) and that Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin may each be deemed to beneficially own 12,792,480 shares (4.1%) based on 315,596,127 Shares outstanding as of March 23, 2026. The statement describes shared voting and dispositive power and notes certain shares issuable upon conversion of warrants.
Core Scientific, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on directors, executive compensation and the independent auditor. Five directors were elected, including Adam Sullivan with 217,650,785 votes for and 2,469,826 withheld, and Elizabeth Crain with 215,074,279 for and 5,046,332 withheld.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 138,785,477 votes for, 79,166,695 against and 2,168,439 abstentions. They also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 262,833,296 votes for, 313,161 against and 1,752,370 abstentions.
Core Scientific, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on directors, executive compensation and the independent auditor. Five directors were elected, including Adam Sullivan with 217,650,785 votes for and 2,469,826 withheld, and Elizabeth Crain with 215,074,279 for and 5,046,332 withheld.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 138,785,477 votes for, 79,166,695 against and 2,168,439 abstentions. They also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 262,833,296 votes for, 313,161 against and 1,752,370 abstentions.
Core Scientific, Inc. ownership disclosure: a group of affiliated broker‑dealers led by Susquehanna entities reports beneficial ownership of 14,631,891 shares, representing 4.6% of the class. The filing states 315,594,802 Shares outstanding as of March 23, 2026. The reported holdings include option and warrant positions: 12,963,500 options and various warrants and options held across the reporting entities. The filing is a joint Schedule 13G/A by G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC, and includes a joint filing agreement.
Core Scientific, Inc. ownership disclosure: a group of affiliated broker‑dealers led by Susquehanna entities reports beneficial ownership of 14,631,891 shares, representing 4.6% of the class. The filing states 315,594,802 Shares outstanding as of March 23, 2026. The reported holdings include option and warrant positions: 12,963,500 options and various warrants and options held across the reporting entities. The filing is a joint Schedule 13G/A by G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC, and includes a joint filing agreement.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock on May 11, 2026 in open-market transactions. The sales occurred in two blocks at weighted average prices of $22.8162 and $23.3916 per share. The filing states the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily. After these sales, Duchene continues to hold a substantial direct equity position in the company, so the activity represents a small portion of his overall holdings.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock on May 11, 2026 in open-market transactions. The sales occurred in two blocks at weighted average prices of $22.8162 and $23.3916 per share. The filing states the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily. After these sales, Duchene continues to hold a substantial direct equity position in the company, so the activity represents a small portion of his overall holdings.